Tab%25252525252525252525252525252520linagliptin

# Linagliptin ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors for its primary biliary excretion rather than renal clearance. ## Primary Indications Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). ## Adult Dosing Standard dose: 5 mg orally once daily. Maximum dose: 5 mg daily. ## Pediatric Dosing Safety and efficacy have not been established in pediatric patients under 18 years of age. ## Dose Adjustments * **Renal Impairment:** No dose adjustment required. * **Hepatic Impairment:** No dose adjustment required. * **Concomitant Use:** If used with a strong CYP3A4 or P-glycoprotein inducer (e.g., rifampin), clinical efficacy may be reduced. Consider alternative agents if glycemic control is inadequate. ## Contraindications * History of a serious hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions). * Type 1 diabetes or treatment of diabetic ketoacidosis (not effective). ## Adverse Effects * **Common:** Nasopharyngitis, upper respiratory tract infections, diarrhea, cough. * **Serious:** Acute pancreatitis (discontinue if suspected), severe and disabling arthralgia, bullous pemphigoid, and hypersensitivity reactions. * **Hypoglycemia:** Risk is low when used as monotherapy; increased risk when used with insulin secretagogues (e.g., sulfonylureas) or insulin. ## Key Drug Interactions * **CYP3A4/P-gp Inducers:** Strong inducers (e.g., rifampin, carbamazepine, phenytoin) can decrease linagliptin plasma concentrations. * **Insulin/Secretagogues:** May require dose reduction of the secretagogue or insulin to mitigate hypoglycemia risk. ## Monitoring * **HbA1c:** Typically every 3–6 months. * **Renal Function:** While not required for dosing, monitoring baseline and periodic renal function is standard practice in T2DM. * **Clinical:** Monitor for signs of pancreatitis (persistent, severe abdominal pain) and bullous pemphigoid (blistering or erosions). ## Clinical Pearls * Linagliptin is the only DPP-4 inhibitor that does not require renal dose modification. * It may be taken without regard to meals. * If a dose is missed, take it as soon as remembered, but do not take two doses on the same day. * Linagliptin has not been studied in combination with insulin or as a replacement for insulin; generally avoided in patients with a history of pancreatitis. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practice and drug labeling vary by region. Always verify specific dosing, safety requirements, and prescribing information via the current local manufacturer’s package insert or a verified clinical database (e.g., Lexicomp, UpToDate) before prescribing or administering medication.